These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 11473030)

  • 1. Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor.
    Burcelin R; Da Costa A; Drucker D; Thorens B
    Diabetes; 2001 Aug; 50(8):1720-8. PubMed ID: 11473030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic effect of portal glucose and glucagon-like peptide-1 to lower systemic glucose and stimulate counter-regulatory hormones.
    Ionut V; Hucking K; Liberty IF; Bergman RN
    Diabetologia; 2005 May; 48(5):967-75. PubMed ID: 15830188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of effect of exendin-4 and glucagon-like peptide-1-(7,36)-amide on insulin action in non-diabetic humans.
    Vella A; Shah P; Reed AS; Adkins AS; Basu R; Rizza RA
    Diabetologia; 2002 Oct; 45(10):1410-5. PubMed ID: 12378382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Portal glucose infusion in the mouse induces hypoglycemia: evidence that the hepatoportal glucose sensor stimulates glucose utilization.
    Burcelin R; Dolci W; Thorens B
    Diabetes; 2000 Oct; 49(10):1635-42. PubMed ID: 11016446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insulin-independent effects of GLP-1 on canine liver glucose metabolism: duration of infusion and involvement of hepatoportal region.
    Dardevet D; Moore MC; Neal D; DiCostanzo CA; Snead W; Cherrington AD
    Am J Physiol Endocrinol Metab; 2004 Jul; 287(1):E75-81. PubMed ID: 15026303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blood glucose lowering and glucagonostatic effects of glucagon-like peptide I in insulin-deprived diabetic dogs.
    Freyse EJ; Becher T; El-Hag O; Knospe S; Göke B; Fischer U
    Diabetes; 1997 May; 46(5):824-8. PubMed ID: 9133550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro.
    Parkes DG; Pittner R; Jodka C; Smith P; Young A
    Metabolism; 2001 May; 50(5):583-9. PubMed ID: 11319721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. No effect of beta-adrenergic blockade on hypoglycaemic effect of glucagon-like peptide-1 (GLP-1) in normal subjects.
    Toft-Nielsen M; Hvidberg A; Hilsted J; Dige-Petersen H; Holst JJ
    Diabet Med; 1996 Jun; 13(6):544-8. PubMed ID: 8799658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucagon-like peptide 1 increases insulin sensitivity in depancreatized dogs.
    Sandhu H; Wiesenthal SR; MacDonald PE; McCall RH; Tchipashvili V; Rashid S; Satkunarajah M; Irwin DM; Shi ZQ; Brubaker PL; Wheeler MB; Vranic M; Efendic S; Giacca A
    Diabetes; 1999 May; 48(5):1045-53. PubMed ID: 10331409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucagon-like peptide I enhances the insulinotropic effect of glibenclamide in NIDDM patients and in the perfused rat pancreas.
    Gutniak MK; Juntti-Berggren L; Hellström PM; Guenifi A; Holst JJ; Efendic S
    Diabetes Care; 1996 Aug; 19(8):857-63. PubMed ID: 8842604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucagon-like peptide-1 (GLP-1) receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats.
    Vahl TP; Tauchi M; Durler TS; Elfers EE; Fernandes TM; Bitner RD; Ellis KS; Woods SC; Seeley RJ; Herman JP; D'Alessio DA
    Endocrinology; 2007 Oct; 148(10):4965-73. PubMed ID: 17584962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.
    Toft-Nielsen MB; Madsbad S; Holst JJ
    Diabetes Care; 1999 Jul; 22(7):1137-43. PubMed ID: 10388979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9-39) amide.
    Kolligs F; Fehmann HC; Göke R; Göke B
    Diabetes; 1995 Jan; 44(1):16-9. PubMed ID: 7813808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exenatide can reduce glucose independent of islet hormones or gastric emptying.
    Ionut V; Zheng D; Stefanovski D; Bergman RN
    Am J Physiol Endocrinol Metab; 2008 Aug; 295(2):E269-77. PubMed ID: 18492781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of intraportal glucagon-like peptide-1 on glucose metabolism in conscious dogs.
    Nishizawa M; Moore MC; Shiota M; Gustavson SM; Snead WL; Neal DW; Cherrington AD
    Am J Physiol Endocrinol Metab; 2003 May; 284(5):E1027-36. PubMed ID: 12569088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers.
    Nauck MA; Heimesaat MM; Behle K; Holst JJ; Nauck MS; Ritzel R; Hüfner M; Schmiegel WH
    J Clin Endocrinol Metab; 2002 Mar; 87(3):1239-46. PubMed ID: 11889194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients.
    Creutzfeldt WO; Kleine N; Willms B; Orskov C; Holst JJ; Nauck MA
    Diabetes Care; 1996 Jun; 19(6):580-6. PubMed ID: 8725855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM.
    Rachman J; Gribble FM; Barrow BA; Levy JC; Buchanan KD; Turner RC
    Diabetes; 1996 Nov; 45(11):1524-30. PubMed ID: 8866556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. No reactive hypoglycaemia in Type 2 diabetic patients after subcutaneous administration of GLP-1 and intravenous glucose.
    Vilsbøll T; Krarup T; Madsbad S; Holst JJ
    Diabet Med; 2001 Feb; 18(2):144-9. PubMed ID: 11251679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure.
    Nauck MA; Sauerwald A; Ritzel R; Holst JJ; Schmiegel W
    Diabetes Care; 1998 Nov; 21(11):1925-31. PubMed ID: 9802745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.